Early data show Achillion in the race for all-oral combo for hepatitis C
This article was originally published in Scrip
Achillion Pharmaceuticals could be a contender in the race to develop an all-oral combination hepatitis C therapy based on positive early data from an ongoing Phase II clinical trial for the New Haven, Connecticut-based company's protease inhibitor sovaprevir (ACH-1625).
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.